RT Journal Article SR Electronic T1 What is the optimal approach to the administration of intraperitoneal chemotherapy in ovarian cancer? JF International Journal of Gynecologic Cancer JO Int J Gynecol Cancer FD BMJ Publishing Group Ltd SP 36 OP 39 DO 10.1111/j.1525-1438.2007.01103.x VO 18 IS Suppl 1 A1 M. Markman YR 2008 UL http://ijgc.bmj.com/content/18/Suppl_1/36.abstract AB Three well-designed and conducted randomized phase 3 trials have revealed that the intraperitoneal administration of cisplatin-based chemotherapy as primary treatment of small-volume residual advanced ovarian cancer improves both progression-free and overall survivals compared to an all intravenous cisplatin-based regimen. Based on very reasonable extrapolations from existing evidence-based data, a number of possible “options” can be proposed that use the intraperitoneal route for delivery of chemotherapy in this clinical setting